CD154
免疫系统
免疫学
免疫疗法
CD40
单克隆抗体
移植
医学
抗体
生物
细胞毒性T细胞
内科学
体外
生物化学
作者
David F. Pinelli,Mandy L. Ford
出处
期刊:Immunotherapy
[Future Medicine]
日期:2015-04-01
卷期号:7 (4): 399-410
被引量:47
摘要
Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment in clinical trials following a number of thromboembolic complications. However, recent mechanistic studies have identified the mechanism of these adverse events, as well as detailed a myriad of interactions between CD40 and CD154 on a wide variety of immune cell types and the critical role of this pathway in generating both humoral and cell-mediated alloreactive responses. This has led to resurgence in interest and the potential resurrection of anti-CD154 and anti-CD40 antibodies as clinically viable therapeutic options.
科研通智能强力驱动
Strongly Powered by AbleSci AI